Towards a better selection of systemic treatment for patients with ER-positive HER2-negative breast cancer: the use of prognostic and predictive markers in early and metastatic setting KU Leuven
Worldwide, breast cancer represents about 25% of all cancers in women. There is extensive research effort into this highly complex and heterogeneous disease comprising many different histological and molecular subtypes with luminal, oestrogen receptor (ER)-positive human epidermal growth factor receptor 2 (HER2)-negative tumours being the most frequent subtype. Even within this subtype, there is a lot of heterogeneity, which complicates accurate ...